Inclusion Criteria:

          -  Advanced or metastatic NSCLC, histologically confirmed at diagnosis of NSCLC,
             documented negative test results for EGFR and ALK genomic alterations, and no known
             genomic alterations in ROS1, NTRK, BRAF, or other driver oncogenes with approved
             therapies (actionable genomic alterations).

          -  Documentation of radiological disease progression while on or after receiving the most
             recent treatment regimen for advanced or metastatic NSCLC.

          -  Received at least 1 regimen of platinum-based chemotherapy and have at least 1 regimen
             of PD-1/PD-L1 directed immunotherapy, either in combination or sequentially.
             Participants with a documented PD-L1 tumor proportion score of <1% must have been
             previously treated with at least 1 regimen of platinum-based chemotherapy with or
             without prior PD-1/PD-L1 immunotherapy.

          -  Willing and able to undergo a mandatory tumor biopsy.

          -  Archival tumor tissue from initial diagnosis, to the extent that archival tumor tissue
             is available, for measurement of TROP2 expression levels or other biomarkers.

          -  Has adequate bone marrow reserve and organ function at baseline within 7 days prior to
             Cycle 1 Day 1

        Exclusion Criteria:

          -  Experienced grade 3 or higher immune-related adverse events with prior immunotherapy
             treatment

          -  Received a live vaccine within 30 days prior to the first dose of study treatment.

          -  Active, known, or suspected autoimmune disease.

          -  Has a condition requiring systemic treatment with either corticosteroids (>10 mg daily
             prednisone equivalent) or other immunosuppressive medications within 14 days of Cycle
             1 Day 1.

          -  Prior allogenic organ transplantation

          -  Known allergy or history of severe hypersensitivity reactions to either the drug
             substances or inactive ingredients (including but not limited to polysorbate 80)

          -  Uncontrolled or significant cardiac disease

          -  Has spinal cord compression or clinically active central nervous system metastases,
             defined as untreated and symptomatic, or requiring therapy with corticosteroids or
             anticonvulsants to control associated symptoms.

          -  History of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required
             steroids, has current ILD/pneumonitis, or where suspected ILD/ pneumonitis cannot be
             ruled out by imaging at screening.

          -  Clinically severe pulmonary compromise resulting from intercurrent pulmonary
             illnesses.

          -  Has other primary malignancies, except adequately resected nonmelanoma skin cancer,
             curatively treated in situ disease, or other solid tumors curatively treated, with no
             evidence of disease for >5 years.